COMMUNIQUÉS West-GlobeNewswire

Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
07/01/2019
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments [...]
Ziopharm Oncology Posts Letter to Stockholders
07/01/2019
BOSTON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today posted and released the following letter: Dear Fellow Stockholders, With the 37 th Annual J.P. Morgan Healthcare Conference upon us [...]
Medexus Files Business Acquisition Report
07/01/2019
MONTREAL, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “ Company ” ) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report (“BAR”) on [...]
Medexus présente une déclaration d’acquisition
07/01/2019
MONTRÉAL, 07 janv. 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (anciennement Pediapharm Inc.) (la « Société ») (TSXV : MDP, OTCQB : PDDPF) a annoncé aujourd’hui la présentation d’une déclaration d’acquisition [...]
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
07/01/2019
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, thoracic, lung, gastrointestinal [...]
Nanobiotix et le MD Anderson Cancer Center annoncent une collaboration clinique globale de grande envergure portant sur NBTXR3
07/01/2019
La collaboration comporte dans un premier temps neuf nouveaux essais cliniques de phase I/II avec NBTXR3, premier produit d’une nouvelle classe de Nanobiotix, dans six types de cancer différents - cancers de la tête et [...]
Holding(s) in Company
07/01/2019
Holding(s) in Company January 7, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Shire Plc JE00B2QKY057 1b. [...]
eSight Proudly Announces 40% Price Reduction on Breakthrough Electronic Glasses for The Visually Impaired —Marking Its Largest Affordability Advancement Ever
07/01/2019
Rapid growth makes price reduction from $9,500 USD to $5,950 USD possible, providing greater accessibility to life-changing, vision-enhancing, and mobility-enabling device for the visually impaired TORONTO and LOS [...]
VALNEVA Announces its Intention to Delist from the Vienna Stock Exchange
07/01/2019
Valneva Announces its Intention to Delist from the Vienna Stock Exchange Trading will be centralized on Euronext Paris Saint-Herblain (France), January 7, 2019 - Valneva SE ("Valneva"), a biotech company developing and [...]
VALNEVA annonce son intention de mettre fin à sa cotation à la bourse de Vienne
07/01/2019
Valneva annonce son intention de mettre fin à sa cotation à la bourse de Vienne L'échange des actions Valneva sera centralisé sur Euronext Paris Saint-Herblain (France), 7 janvier 2019 - Valneva SE ("Valneva" ou "le [...]
Bilan Annuel du contrat de liquidité contracté par Eurobio Scientific avec Louis Capital Markets
07/01/2019
BILAN ANNUEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC LOUIS CAPITAL MARKETS Paris, le 7 janvier 2019 – 17h45 Au titre du contrat de liquidité portant sur les actions de la société Eurobio Scientific [...]
Virbac : Declaration of the number of shares and voting rights as of December 2018, 31.
07/01/2019
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote au 31 Décembre 2018
07/01/2019
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]
Schuylkill Center Achieves American Nurses Credentialing Center Pathway to Excellence in Long Term Care Designation
07/01/2019
KENNETT SQUARE, Pa., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Schuylkill Center, a skilled nursing facility affiliated with Genesis HealthCare in Pottsville, PA, is pleased to announce it has achieved the Pathway to Excellence [...]
Ossur Hf : Transactions in relation to share buyback program
07/01/2019
Announcement no. 01/2019 7 January 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]
PSI Raises Record Amount for Cancer Victims at its 21st Annual Golf Tournament
07/01/2019
ARLINGTON, Va., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Planned Systems International, Inc. (PSI), a leading provider of Health IT solutions to the federal government, is pleased to announce that it raised a record amount for [...]
ChemioCare Strengthens Executive Management Team
07/01/2019
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a Platform Company based on proprietary transdermal delivery today announced the appointment of Jamie Oliver, Pharm.D PhD [...]
Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS™
07/01/2019
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that it [...]
Merit Medical to Present at Needham Growth Conference
07/01/2019
SOUTH JORDAN, Utah, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic [...]

Pages